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Abstract. Regulation of the cell cycle is essential for 
carcinogenesis. The cell cycle is controlled by cyclin-depen-
dent kinases (CDKs), which are upregulated by cyclins and 
downregulated by CDK inhibitors (CDKIs). Decreased p27Kip1 
expression has been associated with survival rate, tumor 
size, histological differentiation and the presence of lymph 
node metastasis in patients with various types of cancer. The 
aim of the current study is to provide a literature review on 
the association between p27Kip1 expression and the clinical 
and pathological aspects of head and neck squamous cell 
carcinoma (HNSCC), and the expression of other CDKIs of 
the Cip/Kip family and cyclins. Throughout the literature, 
different methodologies were used to determine the immuno-
histochemical expression of p27Kip1; thus, results concerning 
p27Kip1 expression in HNSCC vary widely. However, it has now 
been confirmed that p27Kip1 is underexpressed in SCC cells. 
p27 may be a promising marker for determining the prognosis 
of HNSCC, despite the marked variability of the results 
obtained. An association between p27 expression and survival 
rate, time to recurrence and tumor stage has been observed. 
Based on the information currently available, it is premature 
to recommend the analysis of p27Kip1 expression in guiding 
HNSCC treatment planning. However, although relatively 
unstudied, the correlation between p27Kip1 expression and 
other tumor suppressor genes may turn out to be important 
in determining the prognosis of HNSCC. Further prospective 
studies utilizing standardized laboratory methodologies and 
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1. Introduction
Head and neck cancer is growing in prevalence in many regions 
of the world. Oral and oropharyngeal cancer (excluding naso-
pharyngeal cancer) together represent the sixth most common 
malignant neoplasm, with an estimated annual incidence of 
275,000 cases for oral cancer and 130,300 for oropharyngeal 
cancer, two thirds of which occur in developing countries. 
Approximately 90% of head and neck cancers are squamous 
cell carcinomas (1,2).
The carcinogenetic process includes various phases that are 
necessary for the development and evolution of the neoplasm. 
Cancer is the result of a series of genetic and epigenetic 
alterations that occur in multiple steps in a repeated and inter-
connected manner influenced by the genetic predisposition of 
the individual and by exogenous environmental factors (1,3). 
Collectively, these factors result in a series of molecular altera-
tions, including the inactivation of tumor suppressor genes and 
the activation of oncogenes through deletions, specific muta-
tions, promoted methylation and gene amplification (3,4).
Tumor suppressor genes are implicated in various cell divi-
sion processes, including gene expression regulation, cell cycle 
control, apoptosis programming and genome stability (5). The 
loss of activity of these genes results in an inability to respond to 
the control mechanisms that regulate cell division, resulting in 
uncontrolled cell proliferation, the development of neoplasms 
and their evolution towards more aggressive processes, from 
mild or moderate dysplasia to in situ or invasive carcinoma (5).
Regulation of the cell cycle is an important factor in carci-
nogenesis (6). The cell cycle is controlled by cyclin-dependent 
kinases (CDKs), the activity of which is upregulated by 
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cyclins and downregulated by CDK inhibitors (CDKIs). CDKs 
receive signals promoting or inhibiting cell division, thereby 
coordinating the progress of the cell cycle (6). For example, 
the transition from G1-S phase is regulated by the activity of 
cyclin G1/CDK complexes composed of CDK4 and CDK6, 
which are activated upon association with cyclin D, and 
CDK2, which is activated upon binding with cyclin E (6). This 
activity is essential for transition of the restriction point at the 
late stage of G1 (6,7).
The activity of these CDK enzymes is restricted by 
the inhibitory action of two major groups of CDKIs: The 
INK4 family, which comprises the inhibitors p15INK4B, 
p16INK4A, p18INK4C and p19WAF1; and the Cip/Kip family, 
which comprises p21Cip1 (8), p27Kip1 and p57Kip2. The 
Cip/Kip family inhibits cyclin/CDK complexes, including 
cyclin D/CDK4, cyclin D/CDK2, cyclin E/CDK2 and 
cyclin A/CDK2 (Fig. 1)  (9,10).
First discovered in 1993, p27Kip1 exhibits a unique respon-
siveness pattern to a wide range of mitogenic and antimitogenic 
signals, making it notably different from the other two 
members of the CDKI Cip/Kip family. For example, p27 can 
inhibit directly without mediators cyclin D and CDK4/6 (11). 
Although p27 mutations are rare in human tumors, decreased 
p27 expression has been associated with survival rate, tumor 
size, histological differentiation and the presence of lymph node 
metastasis in patients with various types of cancer (12-15). The 
mechanism by which p27 is silenced remains unclear: Whilst 
its expression is regulated transcriptionally and translationally, 
its levels are predominantly regulated by ubiquitin-dependent 
proteolysis mechanisms (16).
The aim of the current study is to provide a literature review 
on the association between p27 expression and the clinical and 
pathological aspects of HNSCC, the expression of CDKIs of 
the Cip/Kip family and cyclins.
2. p27 expression in HNSCC 
The Cochrane database, MEDLINE and EMBASE were 
searched on January 27, 2014, using the following keywords: 
̔p27 oral squamous cell carcinoma ,̓ ̔p27 head and neck 
squamous cell carcinoma̓ and ̔p27 mouth neoplasms .̓ From 
this search, 29 studies of p27 expression in HNSCC were 
identified, the results of which varied widely (17‑45). Different 
methodologies were used to determine the immunohisto-
chemical expression of p27: Certain studies used a quantitative 
analysis of the percentage of stained cells, whereas the vast 
majority used a semi-quantitative analysis, although with 
different degrees of cell and sample staining. The various anti-
bodies used were also applied at different concentrations. In 
order to compare the results, Table I shows the percentage of 
tumors with positive expression as reported by various studies; 
different definitions of positivity have been used, depending 
on the methodology used in each case. A wide variability was 
observed, with a range of 3-89%. By contrast, the difference 
in positivity rate between studies that employed a quantitative 
analysis was markedly lower, with the p27 score varying from 
10±10 to 56.4±16.2% (Table II).
Thus, differences in expression between the different 
working groups may be due to differences in immunohis-
tochemistry, in addition to population characteristics and 
specimen variation. Similarly, it is essential to standardize 
semi-quantitative analysis methods to allow methodological 
unification of the different studies, and thus enable performance 
of systematic reviews and meta-analyses.
3. Progression of p27 expression
Numerous studies have investigated p27 expression throughout 
various phases of HNSCC progression, comparing normal 
mucosa with dysplastic lesions, carcinoma in situ, verrucous 
carcinoma and SCC (Table III). In certain of these studies, the 
comparison was performed qualitatively on the basis of positive 
or negative expression. Thus, Kudo et al (25) observed that the 
percentage of tumors with positive expression was significantly 
lower in SCC and in lesions with severe dysplasia compared 
with that in normal mucosa (P<0.05). Queiroz et al (39) also 
found that p27 expression is lower in oral squamous cell 
carcinoma (OSCC) and in benign lesions compared with in 
normal tissue (P<0.05). By contrast, Schoelch et al (22) and 
Shintani et al (33) found no statistically significant differences. 
In other studies, a quantitative analysis of the percentage of 
stained cells (p27 score) was conducted. Thus, Jordan et al (19) 
reported that p27 expression in lesions with moderate dysplasia, 
severe dysplasia and SCC is lower than that in normal mucosa 
(P<0.05), whilst Saito et al (23) observed lower p27 expression 
in verrucous carcinoma compared with in SCC (P<0.001). 
Similarly, Kuo et al (29) obtained significantly reduced p27 
expression values in SCC compared with that in dysplastic 
lesions, and in the latter compared with in normal mucosa. 
With regard to the age of the patient at the onset of the 
neoplasm, no statistically significant differences were detected. 
In certain studies, the mean age of patients with tumors positive 
and negative for p27 expression was calculated, and no differ-
ences were observed between the two (18,21,28). Similarly, 
other studies compared the percentage of tumors positively 
expressing p27 in younger and older patients (below and above 
the mean cohort age, respectively) and also identified no differ-
ences (29,32,41,46).
Regarding gender, no differences in p27 expression were 
observed between males and females (21,28,32,41).
The results concerning survival are controversial (17,18, 
21,24-26,28,29,32,38,41,43,45,46). In the majority of solid 
tumors, p27 expression silencing is associated with a decrease 
in the five-year survival rate. As can be seen in Table IV, 
in the case of HNSCC, the majority of studies have also 
reported similar findings, some with statistically significant 
differences (21,24,27-29,33,38,41). However, in studies where 
improved survival rates were observed for tumors with nega-
tive p27 expression, the differences were not statistically 
significant (18,32,42,45).
Relapse rate has been analyzed to a lesser extent. Studies 
by Perisanidis et al (43) and Monteiro et al (42) analyzed 
the risk of relapse and observed no significant differ-
ences between tumors with different p27 expression values. 
Canzonieri et al (44) observed a lower p27 expression positivity in 
tumors with relapse, however, the differences were not statistically 
significant. With regard to the time at which relapse occurred, 
Venkatesan et al (24) reported that the mean was 324 days in 
patients with tumors exhibiting low p27 expression levels, signifi-
cantly lower than for patients with high expression levels.
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The presence of lymph node metastasis is a clinicopatho-
logical factor known to be associated with poorer prognosis. 
As such, it is important to determine whether any association 
exists between p27 silencing and the appearance of lymph 
node metastasis. The majority of published studies report that 
patients with a positive lymph node metastasis status have 
reduced p27 expression levels compared with those without 
lymph node metastasis (21,27,33,36); in studies that reported 
contrasting results, the differences were not statistically 
significant (20,29).
Advanced tumor stages are also associated with poorer 
prognosis in HNSCC. Thus, in theory, lower p27 expres-
sion levels should be observed in tumors of more advanced 
stages. Indeed, all studies identified in the literature that 
Table I. Semi-quantitative analysis of immunohistochemical p27Kip1 expression in HNSCC.
 HNSCC  Definition of Positive 
Author, year (reference) cases, n Location positivity, % cases, % Antibody dilution
Kudo et al, 1998 (17) 70 Oral 30 13 Transduction 1:100
Fujieda et al, 1999 (18) 60 Oral/oropharynx 40 30 Oncogene
Ito et al, 1999 (20) 43 Oral 30 14 Transduction 1:500
Mineta et al, 1999 (21) 94 Tongue 50 26 Transduction 1:100
Schoelch et al, 1999 (22) 20 Oral/oropharynx 33 75 Novocastra 1:25
Venkatesan et al, 1999 (24) 35 Oral/oropharynx 11 77 Transduction 1:1,000
Kudo et al, 2000 (25) 17 Oral 30 59 Transduction 1:100
Kapranos et al, 2001 (26) 31 Oral 10 65 Santa Cruz 1:50
Kudo et al, 2001 (27) 37 Oral 5 49 Transduction 1:100
Harada et al, 2002 (28) 81 Oral 50 63 Novocastra 1:100
Kuo et al, 2002 (29) 63 Oral 11 25 Transduction 1:500
Shintani et al, 2002 (30) 117 Oral 5 64.1 Dakopatts 1:1,000
Choi et al, 2003 (32) 30 Orala 5 36.6 Neo Markers 1:100
Shintani et al, 2003 (33) 75 Oral 25 26.6 Transduction 1:100
Kitajima et al, 2004 (35) 63 Oral 30 51 Transduction 1:100
Rodolico et al, 2004 (36) 95 Lower lip 19.7 70 Transduction 1:1,200
Rodolico et al, 2005 (37) 97 Lower lip 20 78 Transduction 1:1,200
Filies et al, 2007 (38) 189 Oral 1 20 Pharmingen 1:1,000
Queiroz et al, 2010 (39) 34 Oral 50 3 Santa Cruz 1:100
Martín-Ezquera et al, 2011 (40) 49 Oral 5 38 BD Biosciences 1:100
Gao et al, 2012 (41) 206 Oral 10 60.2 Zhongshan 1:30
Monteiro et al, 2012 (42) 51 Oral 25 89 Novocastra 1:20
Perisanidis et al, 2012 (43) 111 Oral/oropharynx 50 69 Neo Markers
Canzonieri et al, 2012 (44) 25 Oropharynx/hypopharynx/ 5 25 Transduction 1:100
  larynx
aAll but two tumors (in the larynx and parotid) were oral. HNSCC, head and neck squamous cell carcinoma.
 
Table II. Quantitative analysis of immunohistochemical p27Kip1 expression in HNSCC.
Author, year (reference) HNSCC cases, n Location p27 score, % Antibody dilution
Jordan et al, 1998 (19) 8 Oral 28.7±5.1 Transduction 1:500
Fujieda et al, 1999 (18) 60 Oral/oropharynx 31.1±30  Oncogene
Saito et al, 1999 (23) 44 Oral 24±6 Transduction 1:5,000
Kapranos et al, 2001 (26) 31 Oral 56.4±16.2 Santa Cruz 1:50
Kuo et al, 2002 (29) 63 Oral 10±10 Transduction 1:500
Rodolico et al, 2004 (36) 95 Lower lip 19.7 Transduction 1:1,200
Rodolico et al, 2005 (37) 97 Lower lip 26.4 Transduction 1:1,200
Zhang et al, 2013 (45) 110 Oral 55.46 Zhongshan
HNSCC, head and neck squamous cell carcinoma.
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relate p27 expression with tumor stage report that expres-
sion is reduced in the advanced stages compared with 
in earlier stages (18,21,27-29,32,33,41). Furthermore, the 
majority of studies reported statistically significant differ-
ences (18,21,27,41), thereby, to some extent, confirming that 
p27 silencing is important role in the development of HNSCC. 
Thus, if p27 expression is associated with tumor stage, tumor 
size should also be related. However, in the few studies that 
have investigated the correlation between tumor size and p27 
expression, the results obtained were not consistent with this 
hypothesis. Mineta et al (21), for example, reported statistically 
significant differences for tumor stage, but no such differences 
for tumor size. These findings were in accordance with those 
of Harada et al (28) and Kuo et al (29), who observed a trend 
in which p27 was overexpressed in smaller tumors.
With regard to tumor differentiation, although reduced 
p27 expression may be expected in poorly differentiated 
tumors, studies into the correlation between p27 expression 
and tumor differentiation indicate a tendency for this gene to 
be silenced in poorly differentiated tumors; however, the vast 
majority of studies report no statistically significant differ-
ences (20,21,27,29,32,33,41). Harada et al (28) is the only study 
to have identified a significant correlation between histological 
grade and decreased p27 expression.
Concerning other clinicopathological factors, such as 
smoking habit, alcohol consumption, tumor invasion and tumor 
depth, no statistically significant differences indicating any 
association with these factors and p27 expression have been 
reported in any studies, to the best of our knowledge (17-45).
Thus, regarding the multistep progression of oral cancer, 
almost all studies confirm that p27 expression is reduced as 
the degree of dysplasia or the differentiation of the tumor 
increases.
4. Correlation between expression of p27 and genes from 
the Cip/Kip family
In a similar manner to p27, the other members of the Cip/Kip 
family, p21Cip1 and p57Kip2, also inhibit cyclin/CDK complexes 
by blocking the cell cycle at the G1-S phase checkpoint. 
However, although Fan et al (47) considered p57 expression 
to be a good prognostic marker for OSCC, it has received 
relatively little attention. Therefore, the current review will 
focus more on the correlation between p21 and p27. As is the 
case for p27, a loss of p21 expression is observed in HNSCC. 
However, according to Shintani et al (30), this occurs during 
the initial stages of carcinogenesis and, probably as a result, 
the correlation between p21 expression and the clinicopatho-
logical parameters is highly variable, although the appearance 
of lymph node metastases is often related to p21 silencing. 
With regard to the association between p21 and p27 expres-
sion, the results in the literature are somewhat unclear. Whilst 
Figure 1. p27Kip1 activity in regulation of the G1/S phase transition. Mitogenic signals promote the formation of cyclin D/CDK4 and cyclin D/CDK6 complexes 
that are inhibited by p27Kip1. Sequestration of p27Kip1 lowers the inhibitory activity and facilitates the activation of cyclin E/CDK2 complex. The formation of 
cyclin D and cyclin E/CDK complexes contribute to Rb phosphorylation, activating E2F family members required for progression of the cell cycle to S phase. 
Cyclin E/CDK2 antagonizes p27Kip1 by phosphorylation, which promotes its degradation. CDK, cyclin-dependent kinase; Rb, retinoblastoma protein.
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Choi et al (32) reported an inverse correlation (P=0.08) 
between the two, this was not related to clinicopathological 
parameters. Similarly, a study by Zhang et al (45) revealed 
a statistically significant correlation between the expression 
of the two genes by way of a Pearson analysis, whereas 
Fillies et al (38) obtained different results, although a different 
statistical test (Cox regression model) was used and thus, the 
results are not comparable. Upon analyzing tumors of the oral 
cavity and larynx together, Kapranos et al (26) also failed 
to find a correlation between the expression of these genes, 
or any differences in survival rate between the four possible 
expression combinations.
Although the results are not entirely convincing, it appears 
that the activity of p27 is independent of other cell cycle regu-
lators of the Cip/Kip family.
5. Correlation between p27 expression and cyclins
The present study focussed on reviewing the association 
between p27 expression and cyclin expression. In contrast 
to p27 expression, a number of studies have reported that 
cyclins A, D, and E are overexpressed in SCC compared with 
in normal mucosa, thereby confirming the cyclin‑inhibitory 
role of p27. Various studies have also reported that overex-
pression of cyclins is associated with tumor stage, histological 
differentiation of the tumor and the presence of lymph node 
metastases, thereby affecting the prognosis of patients in terms 
of survival rate and time to recurrence. Pignataro et al (48) 
investigated the correlation between p27 and cyclin D1 
expression in HNSCC, including tumors of the larynx, and 
observed an inverse correlation whereby the majority of 
tumors that exhibit positive p27 expression also present nega-
tive cyclin D1 expression, and those with positive cyclin D1 
expression exhibit negative p27 expression. The same study 
also reported that patients with cyclin D1+/p27- tumors have 
a poorer prognosis, whilst those with cyclin D1-/p27+ tumors 
have a better prognosis in terms of survival rate (P=0.0015) and 
time to recurrence (P=0.0001). Rodolico et al (37) found that 
tumors overexpressing cyclin D1 and underexpressing p27 are 
associated with the appearance of lymph node metastases in 
patients with SCCs of the lower lip. Kuropkat et al (31) believe 
that the results obtained in their study, in which no relation-
ship was identified between cyclin D1 expression and time 
to recurrence when p27 expression was also considered, are 
unreasonable, as both overexpression or very low expression 
of cyclin D1 were associated with shorter time-to-recurrence. 
Fujieda et al (18) obtained statistically significant results that 
contradict those found in the literature and current theories of 
cell cycle regulation (12,48,37,31): The results revealed that 
tumors with positive cyclin D1 expression exhibit a higher 
percentage of cells stained by the p27 antibody compared with 
that of tumors with negative cyclin D1 expression (42.7±31.9 
vs. 25.2±29.3%; P=0.001), whereas the majority of previous 
studies have demonstrated an inverse correlation between 
between cyclin D1 and p27 expression.
Ito et al (20) reported a strongly significant inverse 
cor relation between cyclin E and p27 expression 
(cyclin E+/p27-, 33/42; cyclin E+/p27+, 3/42; cyclin E-/p27-, 
2/42; and cyclin E-/p27+, 4/42; P<0.001) but did not inves-
tigate this association with regard to clinicopathological 
factors. Additionally, Jordan et al (19) identified an associa-
tion between increased cyclin A expression and reduced p27 
expression in SCC.
Thus, although further confirmation is required, the litera-
ture to date suggests that the expression of CDKIs is inversely 
correlated with the expression of cyclins A, D, and E (12).
6. Conclusions
A wide variety of tumor behaviors have been reported 
at the different sites in the head and neck (21). Thus, in 
future, more objective analyses and immunohistochemical 
expression studies must be performed at specific anatomical 
locations, as already undertaken by a number of research 
groups (21,36,37).
Various studies of p27 expression in HNSCC have been 
performed over the last two decades, and there is now no doubt 
that p27 is underexpressed in SCC cells (12,13). p27 may be a 
promising marker for determining the prognosis of HNSCC, 
despite the marked variability of the results obtained. An 
association between p27 expression and survival rate, time to 
recurrence and tumor stage has been observed (24,48). Based on 
the information currently available, it is too early to recommend 
the analysis of p27 expression for guiding HNSCC treatment 
planning. Although relatively unstudied, the correlation between 
p27 expression and other tumor suppressor genes may turn out to 
be important for determining the prognosis of HNSCC. However, 
further prospective studies and studies involving standardized 
laboratory methodologies and statistics that allow meta-analyses 
to be performed are required to confirm this proposal.
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